Correction: Triple MAPK inhibition salvaged a relapsed post-BCMA CAR-T cell therapy multiple myeloma patient with a BRAF V600E subclonal mutation

Muhammad Elnaggar^{1

2}, Sarita Agte¹, Paula Restrepo^{1

2}, Meghana Ram¹, David Melnekoff^{1

2

3}, Christos Adamopoulos^{1

2}, Mark M Stevens⁴, Katerina Kappes¹, Violetta Leshchenko¹, Daniel Verina¹, Sundar Jagannath¹, Poulikos I Poulikakos^{1

2}, Samir Parekh¹, Alessandro Laganà^{5

6

7}

Affiliations

¹ Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
² Department of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
³ Graduate School of Biomedical Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
⁴ Travera, Medford, MA, USA.
⁵ Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA. alessandro.lagana@mssm.edu.
⁶ Department of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA. alessandro.lagana@mssm.edu.
⁷ Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA. alessandro.lagana@mssm.edu.

Published Erratum

Muhammad Elnaggar et al. J Hematol Oncol. 2023.

. 2023 May 8;16(1):52.

doi: 10.1186/s13045-023-01449-x.

¹ Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
² Department of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
³ Graduate School of Biomedical Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
⁴ Travera, Medford, MA, USA.
⁵ Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA. alessandro.lagana@mssm.edu.
⁶ Department of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA. alessandro.lagana@mssm.edu.
⁷ Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA. alessandro.lagana@mssm.edu.

No abstract available

Erratum for

Triple MAPK inhibition salvaged a relapsed post-BCMA CAR-T cell therapy multiple myeloma patient with a BRAF V600E subclonal mutation.
Elnaggar M, Agte S, Restrepo P, Ram M, Melnekoff D, Adamopoulos C, Stevens MM, Kappes K, Leshchenko V, Verina D, Jagannath S, Poulikakos PI, Parekh S, Laganà A. Elnaggar M, et al. J Hematol Oncol. 2022 Aug 17;15(1):109. doi: 10.1186/s13045-022-01330-3. J Hematol Oncol. 2022. PMID: 35978321 Free PMC article.

1. Elnaggar M, et al. Triple MAPK inhibition salvaged a relapsed post-BCMA CAR-T cell therapy multiple myeloma patient with a BRAF V600E subclonal mutation. J Hematol Oncol. 2022;15:109. doi: 10.1186/s13045-022-01330-3. - DOI - PMC - PubMed